The role of bone marrow transplantation in acute promyelocytic leukemia

被引:31
作者
Nabhan, C [1 ]
Mehta, J [1 ]
Tallman, MS [1 ]
机构
[1] Northwestern Univ, Sch Med, Div Hematol & Oncol, Robert H Lurie Comprehens Canc Ctr,Dept Med, Chicago, IL 60611 USA
关键词
acute promyelocytic leukemia;
D O I
10.1038/sj.bmt.1703119
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Acute promyelocytic leukemia (APL) is characterized by a specific gene rearrangement and the generation of the PML-RAR alpha fusion transcript which results from a translocation between chromosomes 15 and 17. Targeted therapy with all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy results in an apparent cure in 70-80% of patients. Both allogeneic (ALLO) and autologous (AUTO) hematopoietic stem cell transplantation (HSCT) are effective in acute myeloid leukemia (AML), but their role in APL is not clear given the excellent outcome with ATRA and chemotherapy. Several retrospective studies have analyzed the outcome of patients undergoing AUTO or ALLO-HSCT in first (CRI) or second (CR2) complete remission. Most of these studies have shown significant transplant-related mortality (TRM) with ALLO-HSCT, but a reduction in relapse rate compared with AUTO-HSCT. The high TRM with ALLO-HSCT and the excellent outcome with ATRA and chemotherapy do not justify recommending this procedure for the majority of patients in CRI. The role of AUTO-HSCT in CRI also is unclear. A small subset of patients at high risk of relapse, possibly identifiable by a high white blood cell count at presentation may benefit from HSCT. Most patients with relapsed disease achieve CR2 with ATRA, arsenic trioxide, or combination therapy. However, it is not known if these responses are sustained or if consolidation with HSCT has a place in this setting. The outcome of AUTO-HSCT in CR2 using stem cells that are negative for PML-RAR alpha is excellent. It is unclear whether ALLO-HSCT from an HLA-identical sibling is superior to AUTO-HSCT with PML-RAR alpha -negative cells in CR2 since the former would be associated with graft-versus-leukemia effects and the latter with lower TRM. Alternatively, arsenic trioxide or re-treatment with ATRA, followed by intensive chemotherapy may also be effective. A randomized prospective clinical trial, or a retrospective analysis of the available data would be useful in answering this critical question.
引用
收藏
页码:219 / 226
页数:8
相关论文
共 67 条
  • [1] BREITMAN TR, 1981, BLOOD, V57, P1000
  • [2] Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial
    Burnett, AK
    Goldstone, AH
    Stevens, RMF
    Hann, IM
    Rees, JKH
    Gray, RG
    Wheatley, K
    [J]. LANCET, 1998, 351 (9104) : 700 - 708
  • [3] AUTOLOGOUS BONE-MARROW TRANSPLANT IN ACUTE MYELOID-LEUKEMIA IN 1ST REMISSION
    CASSILETH, PA
    ANDERSEN, J
    LAZARUS, HM
    COLVIN, OM
    BENNETT, JM
    STADTMAUER, EA
    KAIZER, H
    WEINER, RS
    EDELSTEIN, M
    OKEN, MM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (02) : 314 - 319
  • [4] Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission
    Cassileth, PA
    Harrington, DP
    Appelbaum, FR
    Lazarus, HM
    Rowe, JM
    Paietta, E
    Willman, C
    Hurd, DD
    Bennett, JM
    Blume, KG
    Head, DR
    Wiernik, PH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (23) : 1649 - 1656
  • [5] CASTAIGNE S, 1990, BLOOD, V76, P1704
  • [6] CASTAIGNE S, 1993, BLOOD, V82, P3560
  • [7] Chen G, 1997, Zhonghua Nei Ke Za Zhi, V36, P295
  • [8] Chen GQ, 1996, BLOOD, V88, P1052
  • [9] CHOMIENNE C, 1990, BLOOD, V76, P1710
  • [10] CORTES JE, 1994, CANCER-AM CANCER SOC, V73, P2946, DOI 10.1002/1097-0142(19940615)73:12<2946::AID-CNCR2820731211>3.0.CO